Keith Lamont Cummings - Jul 9, 2024 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Role: Chief Financial Officer
Signature: /s/ Mike Ouimette, attorney-in-fact
Stock symbol: PLRX
Transactions as of: Jul 9, 2024
Transactions value $: $0
Form type: 4
Date filed: 7/11/2024, 04:54 PM
Previous filing: May 6, 2024
Next filing: Jul 12, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PLRX	Common Stock	Award	$0	+21.3K	+7.84%	$0.00	293K	Jul 9, 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 21,313 shares.

Content

On July 28, 2022, the Reporting Person was granted 77,500 performance-vested stock units, the vesting of which were subject to the achievement of various pre-established performance criteria. On July 9, 2024, the Compensation Committee of the Issuer's Board of Directors certified the achievement of the performance criteria tied to the company's total shareholder return relative to the Nasdaq Biotechnology Index, resulting in the vesting of 21,313 shares.